Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases

"Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases." Amyloid, 24(sup1), pp. 109–110

Declaration of interest

This study was sponsored by Pfizer. Editorial support for abstract formatting was provided by Mary Kunjappu, PhD, of Engage Scientific Solutions and was funded by Pfizer. MWC has received support from Pfizer as a clinical trial investigator, for scientific meetings, and as a consultant. HS has received honoraria from Pfizer, Alnylam, GSK, and IONIS. MFB and ASC are employees of Pharmerit International, and MFB is a shareholder of Pharmerit, which was a paid contractor to Pfizer. JAC is an independent contractor to Pharmerit. MS, MH, SF, and LA are full-time employees of Pfizer and hold stock and/or stock options.